#1 Clinical Trials Search in Europe

Azetukalner

Azetukalner is an innovative drug currently being studied in clinical trials for the treatment of Major Depressive Disorder (MDD). This article explores the ongoing research, specifically focusing on a Phase 3 clinical trial called X-NOVA2, which aims to evaluate the efficacy, safety, and tolerability of Azetukalner in adults with moderate-to-severe MDD.

Table of Contents

What is AZETUKALNER?

AZETUKALNER, also known by its synonyms XEN1101, Encukalner, VRX-698, and VRX-621698, is a promising new medication being developed for the treatment of epilepsy[1]. It belongs to a class of drugs called “other antiepileptics,” which means it works differently from traditional seizure medications[2].

How Does AZETUKALNER Work?

While the exact mechanism of action is not fully explained in the provided information, AZETUKALNER is believed to work by targeting specific channels in the brain that are involved in regulating electrical activity. By modulating these channels, it may help to reduce the occurrence of seizures in people with epilepsy[3].

Types of Seizures Treated

AZETUKALNER is being studied for its effectiveness in treating two main types of seizures:

  • Focal Onset Seizures: These are seizures that start in one area of the brain. They can sometimes spread to other areas and may or may not involve a loss of consciousness[1].
  • Primary Generalized Tonic-Clonic Seizures (PGTCS): These are seizures that involve the entire brain from the start. They typically cause a loss of consciousness and convulsions[4].

Clinical Trials

AZETUKALNER is currently being evaluated in several Phase 3 clinical trials. These are large-scale studies designed to confirm the drug’s effectiveness and safety. Some key points about these trials include:

  • They are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either AZETUKALNER or a placebo, and neither the participants nor the researchers know who is receiving which[2].
  • The trials are testing different doses of AZETUKALNER, typically ranging from 10 mg to 25 mg per day[5].
  • The main goal is to see if AZETUKALNER can reduce the frequency of seizures compared to a placebo[4].
  • Researchers are also looking at how quickly the drug starts working and its impact on patients’ quality of life[3].

Dosage and Administration

In the clinical trials, AZETUKALNER is being tested as a once-daily oral medication. The capsules are typically taken by mouth. The doses being studied range from 10 mg to 25 mg per day, with some trials looking at multiple dose levels to determine the most effective and safe dose[5].

Potential Side Effects

As with any medication, AZETUKALNER may cause side effects. The clinical trials are carefully monitoring for any adverse events. Some areas of particular interest include:

  • Changes in vital signs, such as blood pressure and heart rate
  • Effects on liver function
  • Potential neurological side effects
  • Changes in mood or behavior, including any increase in suicidal thoughts
  • Urological symptoms, such as urinary retention

It’s important to note that the full safety profile of AZETUKALNER will be better understood once the clinical trials are completed[3].

Who Can Take AZETUKALNER?

Based on the clinical trial criteria, AZETUKALNER is being studied in:

  • Adults aged 18 to 75 years old
  • People diagnosed with focal epilepsy or primary generalized tonic-clonic seizures
  • Patients who are already taking 1 to 3 other anti-seizure medications but still experiencing seizures

However, there are several conditions that might prevent someone from participating in the trials, such as:

  • A history of certain mental health conditions
  • Severe liver or kidney problems
  • Recent history of drug or alcohol abuse
  • Pregnancy or breastfeeding

It’s important to remember that these criteria are for the clinical trials. If AZETUKALNER is approved for general use in the future, the guidelines for who can take it may be different[4].

Conclusion

AZETUKALNER represents a potential new option for people with epilepsy who continue to have seizures despite current treatments. While the results of the ongoing clinical trials are not yet known, the research community is hopeful that this medication could provide better seizure control and improve the quality of life for many people living with epilepsy. As always, patients should consult with their healthcare providers about the most appropriate treatment options for their individual situation[5].

Aspect Details
Study Name X-NOVA2
Drug Name Azetukalner (also known as XEN1101)
Condition Studied Major Depressive Disorder (MDD)
Study Type Phase 3, randomized, double-blind, placebo-controlled
Dosage 20 mg, once daily with food
Duration 6 weeks
Primary Outcome Measure Change in HAMD-17 score from baseline to Week 6
Secondary Outcome Measures Changes in SHAPS and CGI-S scores

FAQ

  • What is Azetukalner? Azetukalner is a new drug being tested for the treatment of Major Depressive Disorder. It's also known by the name XEN1101 and is taken orally once a day with food.
  • What is the X-NOVA2 study? X-NOVA2 is a Phase 3 clinical trial designed to evaluate Azetukalner's effectiveness, safety, and tolerability in treating moderate-to-severe Major Depressive Disorder in adults.
  • How is the study conducted? The study is randomized, double-blind, and placebo-controlled. This means participants are randomly assigned to either Azetukalner or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
  • What is the dosage of Azetukalner in this study? In the X-NOVA2 study, participants receive 20 mg of Azetukalner, taken orally once a day with food, preferably with the evening meal, for 6 weeks.
  • How is the effectiveness of Azetukalner measured in this study? The main measure of effectiveness is the change in the Hamilton Depression Rating Scale (HAMD-17) score from the beginning of the study to Week 6. Other measures include changes in the Snaith-Hamilton Pleasure Scale (SHAPS) and the Clinical Global Impression of Severity (CGI-S) scores.

Ongoing Clinical Trials on Azetukalner

  • A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

    Recruiting

    3 1
    Investigated drugs:
    Czechia Finland Germany Poland Romania Slovakia +1

  • A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

    Recruiting

    3 1
    Investigated drugs:
    Bulgaria Germany Poland Spain

  • Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Finland +10

  • Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Finland +8

  • Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia France +6

  • A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Bulgaria France Germany Spain

  • Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

    Not recruiting

    3 1
    Investigated drugs:
    Bulgaria Czechia Germany Ireland Italy Latvia +3

  • Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

    Not recruiting

    2 1
    Investigated drugs:
    Germany Italy Spain

Glossary

  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, which significantly impact daily life.
  • Phase 3 Clinical Trial: A large-scale study conducted to confirm the effectiveness and safety of a new treatment, typically involving hundreds to thousands of participants.
  • Randomized: A method of assigning participants to different treatment groups by chance, to reduce bias in the study results.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the actual treatment or placebo.
  • Placebo-controlled: A study that includes a group receiving an inactive substance (placebo) to compare with the group receiving the actual treatment.
  • Monotherapy: The use of a single drug to treat a particular condition.
  • Hamilton Depression Rating Scale (HAMD-17): A 17-item questionnaire used to assess the severity of depression symptoms.
  • Snaith-Hamilton Pleasure Scale (SHAPS): A scale used to measure anhedonia, or the reduced ability to experience pleasure, which is often associated with depression.
  • Clinical Global Impression of Severity (CGI-S): A scale used by healthcare providers to rate the severity of a patient's illness.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-azetukalner-in-reducing-focal-onset-seizures-for-patients-with-epilepsy/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-azetukalner-in-patients-with-focal-onset-seizures/
  3. http://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-tolerability-of-azetukalner-for-patients-with-epilepsy-including-focal-onset-and-primary-generalized-tonic-clonic-seizures/
  4. http://clinicaltrials.eu/trial/study-on-the-effects-of-xen1101-and-placebo-for-patients-with-primary-generalized-tonic-clonic-seizures/
  5. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-azetukalner-for-adults-with-focal-epilepsy-taking-1-to-3-anti-seizure-medications/